Inspira technologies secures $22.5 million purchase order, launches full revenue execution phase

Ra'anana, israel, july 02, 2025 (globe newswire) -- inspira™ technologies oxy b.h.n. ltd. (nasdaq: iinn) ("inspira," “inspira technologies,” or the "company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has secured a binding $22.5 million purchase order for its fda-cleared art100 system, representing a major commercial inflection point for the company. the order was placed by a privately held company headquartered outside the united states, in a global strategic hub, with an established track record and active commercial ties to both government entities and institutional healthcare customers.
IINN Ratings Summary
IINN Quant Ranking